XERS Xeris Pharmaceuticals Inc

Price (delayed)

$6.15

Market cap

$1.06B

P/E Ratio

87.86

Dividend/share

N/A

EPS

$0.07

Enterprise value

$1.21B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 96

Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

Highlights
The net income has soared by 127% YoY
XERS's EPS has soared by 123% year-on-year
XERS's equity has surged by 137% year-on-year but it is down by 5% since the previous quarter
XERS's quick ratio is up by 29% year-on-year but it is down by 4.1% since the previous quarter

Key stats

What are the main financial stats of XERS

XERS stock price

How has the Xeris Pharmaceuticals stock price performed over time
Intraday
4.41%
1 week
-2.69%
1 month
-3%
1 year
38.83%
YTD
-21.66%
QTD
6.03%

Financial performance

How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$314.85M
Gross profit
$270.44M
Operating income
$35.9M
Net income
$12.01M
Gross margin
85.9%
Net margin
3.8%
The net income has soared by 127% YoY
The net margin has soared by 119% YoY
The gross profit has grown by 48% YoY and by 8% from the previous quarter
The operating income has grown by 44% since the previous quarter

Price vs fundamentals

How does XERS's price correlate with its fundamentals

Growth

What is Xeris Pharmaceuticals's growth rate over time

Valuation

What is Xeris Pharmaceuticals stock price valuation
P/E
87.86
P/B
81.5
P/S
3.33
EV/EBIT
29.72
EV/EBITDA
22.62
EV/Sales
3.84
XERS's EPS has soared by 123% year-on-year
XERS's equity has surged by 137% year-on-year but it is down by 5% since the previous quarter
The company's revenue rose by 41% YoY and by 8% QoQ
XERS's price to sales (P/S) is 18% less than its last 4 quarters average of 3.9

Efficiency

How efficient is Xeris Pharmaceuticals business performance
The return on assets has surged by 123% year-on-year
The return on invested capital has increased by 37% since the previous quarter
XERS's ROS is up by 26% since the previous quarter

Dividends

What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XERS.

Financial health

How did Xeris Pharmaceuticals financials performed over time
The total assets is 3.4% more than the total liabilities
XERS's quick ratio is up by 29% year-on-year but it is down by 4.1% since the previous quarter
The total assets has grown by 24% YoY and by 2.2% from the previous quarter
XERS's equity has surged by 137% year-on-year but it is down by 5% since the previous quarter
The debt to equity has grown by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.